Angiocrine Bioscience

New York, United States

Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.

$2.1M raised

Sep 2025

Undisclosed

Biotechnology Health Care Health Diagnostics Therapeutics

Top Investors

California Institute for Regenerative Medicine Gutbrain Ventures

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Angiocrine Bioscience

How much funding has Angiocrine Bioscience raised?

Angiocrine Bioscience has raised $2.1M in total funding. The most recent round was Undisclosed. The last funding was announced in September 2025.

Who are Angiocrine Bioscience's investors?

Angiocrine Bioscience's investors include California Institute for Regenerative Medicine, Gutbrain Ventures.

Where is Angiocrine Bioscience headquartered?

Angiocrine Bioscience is headquartered in New York, United States.

What does Angiocrine Bioscience do?

Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.

What stage is Angiocrine Bioscience at?

Angiocrine Bioscience is at the Undisclosed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 3, 2025.

MLA

"Angiocrine Bioscience — Funding & Investors." VCBacked, September 3, 2025, https://www.vcbacked.co/company/angiocrine-bioscience. Accessed July 3, 2026.

APA

VCBacked. (2025). Angiocrine Bioscience — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/angiocrine-bioscience

Wikipedia (cite web)

{{cite web |title=Angiocrine Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/angiocrine-bioscience |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 3, 2025.